Table 2.

Emibetuzumab-related treatment emergent AEs

Emibetuzumab monotherapy (Part A)
CTCAE term20 mg70 mg210 mg700 mg1,400 mg2,000 mgTotal
n = 6n = 3n = 3n = 5n = 3n = 3N = 23, n (%)
Patients with at least 1 drug-related AE0212016 (26.1)
Diarrhea0110002 (8.7)
Nausea0001012 (8.7)
Vomiting0002002 (8.7)
Abdominal pain0001001 (4.3)
Anorexia0100001 (4.3)
Chills0100001 (4.3)
Fatigue0000011 (4.3)
General disorders and administrations site conditions, other, specify0100001 (4.3)
Emibetuzumab + erlotinib (Part A2)
CTCAE term700 mg1,400 mg2,000 mgTotal
n = 5n = 3n = 6N = 14 (%)
Patients with at least 1 drug-related AE2259 (64.3)
Fatigue0123 (21.4)
Anorexia0112 (14.3)
Creatinine increased0011 (1.7)
Diarrhea0101 (7.1)
Dry skin0011 (7.1)
Endocrine disorders, other, specify0011 (1.7)
General disorders and administrations site conditions, other specify0011 (1.7)
Hypocalcemia0011 (7.1)
Hypotension0011 (7.1.)
Investigations, other, specify0011 (7.1)
Nausea0011 (7.1)
Pain in extremity0011 (7.1)
Peripheral sensory neuropathy0101 (7.1)
Pruritus0101 (7.1)
Rash, acneiform1001 (7.1)
Rash, maculopapular1001 (7.1)
Vomiting0011 (7.1)
Weight loss1001 (7.1)
  • Abbreviations: N, total number of patients; n, number of patients in the specified category.